P1001: Predictive factors of colectomy in patients admitted with Acute Severe Ulcerative ColitisECCO'24Year: 2024
Authors: Karpavičiūtė, V.(1)*;Kiudelis, G.(2);Kupčinskas, J.(2);Kupčinskas, L.(2);
(1)Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Department of Gastroenterology, Kaunas, Lithuania;(2)Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Department of Gastroenterology - Medical Academy, Kaunas, Lithuania;
P1003: Dietary pattern can influence the level of fatigue in patients with Inflammatory Bowel Disease in remissionECCO'24Year: 2024
Authors: Stroie, T.G.(1);Preda, C.M.(1)*;Istratescu, D.(1);Nitescu, M.(2);Manuc, T.E.(1);Manuc, M.(1);Meianu, C.G.(1);Andrei, A.(1);Ciora, C.A.(1);Louis, E.(3);Diculescu, M.M.(1);
(1)Fundeni Clinical Institute, Gastroenterology and Hepatology, Bucharest, Romania;(2)National Institute for Infectious Diseases Prof. Dr. Matei Bals, Infectious Diseases, Bucharest, Romania;(3)University Hospital CHU, Gastroenterology, Liège, Belgium;
P1004: Proportion of agents for refractory ulcerative colitis and the efficacy of immunomodulator in 5-aminosalicylic acid intoleranceECCO'24Year: 2024
Authors: Madarame, A.(1)*;Fukuzawa, M.(1);Naito, S.(1);Yamauchi, Y.(1);Yamaguchi, H.(1);Koyama, Y.(1);Kagawa, Y.(1);Ichimiya, T.(1);Shinohara, H.(1);Nemoto, D.(1);Itoi, T.(1);
(1)Tokyo Medical University Hospital, Gastroenterology and Hepatology, Tokyo, Japan;
P1005: Dose escalated Infliximab in Inflammatory Bowel Disease - Crohn@E@s Colitis Cure (CCC) Data Insights ProgramECCO'24Year: 2024
Authors: Alshiwanna, B.(1)*;Mcnamara, J.(1);Wilson, W.(2);Pipicella, J.L.(3);Ghaly, S.(4);Gearry, R.(5);Begun, J.(6);Williams, A.(1);Lynch, K.(7);Lawrance, I.(8);Schultz, M.(9);Walker, G.(10);Radford-Smith, G.(10);Connor, S.J.(1);Andrews, J.M.(7);
(1)Liverpool Hospital, Gastroenterology and Hepatology, Sydney, Australia;(2)Lyell McEwin Hospital, Anaesthetics, Adelaide, Australia;(3)Ingham Institure for Applied Medical Research, Gastroenterology and Hepatology, Sydney, Australia;(4)St Vincent@E@s Public & Private Hospitals, Gastroenterology and Hepatology, Sydney, Australia;(5)University of Otago, Department of Medicine, Christchurch, Australia;(6)Mater Hospital, Gastroenterology and Hepatology, Brisbane, Australia;(7)Central Adelaide Local Health Network, Gastroenterology and Hepatology, Adelaide, Australia;(8)St John of God Healthcare, Gastroenterology, Perth, Australia;(9)Dunedin Hospital, Gastroenterology and Hepatology, Dunedin, New Zealand;(10)Royal Brisbane and Women@E@s Hospital, Gastroenterology and Hepatology, Brisbane, Australia;
P1006: Assessing sexual health care needs in patients with inflammatory bowel diseaseECCO'24Year: 2024
Authors: Beattie, W.(1)*;Elford, A.(1);Segal, J.(1);Kaushik, V.(1);Downie, A.(1);Mitchell, J.(1);Al-Ani, A.(1);Prentice, R.(1);Christensen, B.(1);
(1)Royal Melbourne Hospital, Gastroenterology, Melbourne, Australia;
P1008: Efficacy and safety of retreatment with upadacitinib after treatment interruption in ulcerative colitis: Data from the phase 3 open-label extension study U-ACTIVATEECCO'24Year: 2024
Authors: Panaccione, R.(1)*;Colombel, J.F.(2);Dubinsky, M.(3);Hisamatsu, T.(4);Remple, V.(5);Garrison, A.(6);Klaff, J.(7);Kujawski, M.(8);Vermeire, S.(9);
(1)University of Calgary, Inflammatory Bowel Disease, Calgary, Canada;(2)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(3)Icahn School of Medicine at Mount Sinai, Pediatric Gastroenterology, New York, United States;(4)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(5)AbbVie Inc, Gastroenterology- Global Medical Affairs, Chicago, United States;(6)AbbVie Inc, Data & Statistical Sciences, Chicago, United States;(7)AbbVie Inc, Immunology Clinical Development, Chicago, United States;(8)AbbVie Inc, Immunology- Gastroenterology, Chicago, United States;(9)University Hospital Leuven, Gastroenterology and Hepatology, Leuven, Belgium;
P1009: Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension studyECCO'24Year: 2024
Authors: D@E@Haens, G.(1)*;Sands, B.E.(2);Ferrante, M.(3);Matsuoka, K.(4);Lindsay, J.O.(5);Blumenstein, I.(6);Mehra, D.(7);Charles, L.(7);Cetin, V.(7);Petersen, A.(7);Wu, H.(7);Wang, D.(8);Jain, A.(7);Hanauer, S.B.(9);
(1)Amsterdam University Medical Center, Gastroenterology, Amsterdam, The Netherlands;(2)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(3)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(4)Toho University Medical Center- Sakura Hospital, Inflammatory Bowel Disease, Sakura, Japan;(5)Barts and the London School of Medicine and Dentistry, Immunobiology, London, United Kingdom;(6)Goethe University Hospital, Inflammatory Bowel Disease, Frankfurt, Germany;(7)Bristol Myers Squibb, n/a, Princeton, United States;(8)Bristol Myers Squibb K. K., n/a, Tokyo, Japan;(9)Northwestern University Feinberg School of Medicine, Crohn@E@s disease and Ulcerative Colitis, Chicago, United States;
P100: Salivary exosomes aggravate colitis via oral-gut axisECCO'24Year: 2024
Authors: Yang, C.(1)*;Chen, J.(1);Wu, J.(1);Zhao, Y.(1);Xu, Y.(1);You, P.(1);Xu, J.(1);Chen, N.(1);
(1)Peking University People’s Hospital, Department of Gastroenterology, Beijing, China;
P1010: Guselkumab improves abdominal pain and bowel urgency symptoms in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction studyECCO'24Year: 2024
Authors: Rubin, D.(1);Panés, J.(2);Feagan, B.(3);Yarandi, S.(4);Huang, K.H.(4);Germinaro, M.(4);Han, C.(4);Miao, Y.(4);Zhang, H.(4);Qiu, Y.(5);Klopocka, M.(6);Duvall, G.(7);Lichtenstein, G.(8);Hisamatsu, T.(9);Bressler, B.(10);Peyrin-Biroulet, L.(11)*;
(1)University of Chicago Medicine Inflammatory Bowel Disease Center, Gastroenterology, Chicago, United States;(2)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(3)Alimentiv Inc, Gastroenterology, London, Canada;(4)Janssen Research & Development- LLC, Gastroenterology, Spring House, United States;(5)The First Affiliated Hospital of Sun Yat-sen University, Gastroenterology and Hepatology, Guangzhou, China;(6)Collegium Medicum- Bydgoszcz- and Nicolaus Copernicus University- Torun´, Gastroenterology, Bydgoszcz, Poland;(7)Christus Trinity Clinic, Gastroenterology, Tyler, United States;(8)8Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania- Center for Inflammatory Bowel Disease, Gastroenterology, Philadelphia, United States;(9)Kyorin University, Gastroenterology and Hepatology, Tokyo, Japan;(10)10The IBD Centre of BC Director- Advanced IBD Training Program Clinical Associate Professor of Medicine- Division of Gastroenterology- University of British Columbia, Gastroenterology, Vancouver, Canada;(11)Nancy University Hospital- Université de Lorraine, Gastroenterology, Nancy, France;QUASAR Clinical Investigators
P1011: Methotrexate polyglutamates in paediatric inflammatory bowel disease: Novel tool for therapeutic drug monitoring?ECCO'24Year: 2024
Authors: Vermeer, E.(1,2,3)*;Struys, E.A.(4);van Limbergen, J.E.(1,2,3);de Boer, N.K.(2,5);de Jonge, R.(4);de Meij, T.G.J.(1,2,3);
(1)Amsterdam UMC, Paediatric Gastroenterology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Amsterdam Gastroenterology- Endocrinology and Metabolism Research Institute, Amsterdam, The Netherlands;(3)Amsterdam UMC, Amsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands;(4)Amsterdam UMC, Laboratory Medicine, Amsterdam, The Netherlands;(5)Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P1012: Dose escalated Ustekinumab in Inflammatory Bowel Disease - Crohn@E@s Colitis Cure (CCC) Data Insights ProgramECCO'24Year: 2024
Authors: Barnett, M.(1)*;Mcnamara, J.(2);Wilson, W.(3);Pipicella, J.(4);Ghaly, S.(5);Gearry, R.(6);Begun, J.(7);Williams, A.(2);Lynch, K.(1);Lawrance, I.(8);Schultz, M.(9);Walker, G.(10);Radford-Smith, G.(10);Connor, S.J.(2);Andrews, J.M.(1);
(1)Central Adelaide Local Health Network, Gastroenterology and Hepatology, Adelaide, Australia;(2)Liverpool Hospital, Gastroenterology and Hepatology, Sydney, Australia;(3)Lyell McEwin Hospital, Anaesthetics, Adelaide, Australia;(4)Ingham Institure for Applied Medical Research, Gastroenterology and Hepatology, Sydney, Australia;(5)St Vincent@E@s Public & Private Hospital@E@s, Gastroenterology and Hepatology, Sydney, Australia;(6)University of Otago, Department of Medicine, Christchurch, New Zealand;(7)Mater Hospital, Gastroenterology and Hepatology, Brisbane, Australia;(8)St John of God Healthcare, Gastroenterology and Hepatology, Perth, Australia;(9)Dunedin Hospital, Gastroenterology and Hepatology, Dunedin, New Zealand;(10)Royal Brisbane and Women@E@s Hospital, Gastroenterology and Hepatology, Brisbane, Australia;
P1013: Placebo rates in Crohn@E@s disease: An individual patient data meta-analysis from multiple randomised controlled trialsECCO'24Year: 2024
Authors: Solitano, V.(1,2,3)*;Hogan, M.(2);Singh, S.(4);Danese, S.(3);Peyrin-Biroulet, L.(5,6,7);Zayadi, A.(2);Zou, G.(2,8);Sands, B.E.(9);Feagan, B.G.(1,2,8);Narula, N.(10,11);Ma, C.(2,12,13);Jairath, V.(1,2,8);
(1)Western University, Division of Gastroenterology, London- ON, Canada;(2)Alimentiv Inc., Medical R&D, London- ON, Canada;(3)Università Vita-Salute San Raffaele, Division of Gastroenterology and Gastrointestinal Endoscopy- IRCCS Ospedale San Raffaele, Milan, Italy;(4)University of California- San Diego, Division of Gastroenterology- Department of Medicine, La Jolla- CA, United States;(5)Nancy University Hospital, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(6)Nancy University Hospital, INFINY Institute, Vandœuvre-lès-Nancy, France;(7)Groupe Hospitalier privé Ambroise Paré, Hartmann Paris IBD center, Neuilly sur Seine, France;(8)Western University, Department of Epidemiology and Biostatistics, London- ON, Canada;(9)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York- NY, United States;(10)McMaster University, Division of Gastroenterology- Department of Medicine, Hamilton- ON, Canada;(11)McMaster University, Farncombe Family Digestive Health Research Institute, Hamilton- ON, Canada;(12)University of Calgary, Division of Gastroenterology & Hepatology, Canlgary- AB, Canada;(13)University of Calgary, Department of Community Health Sciences, Calgary- AB, Canada;
P1014: Faecal loss of vedolizumab is associated with UC severity, lower serum vedolizumab levels and rates of clinical response – Results from the FAVOUR studyECCO'24Year: 2024
Authors: Samaan, M.(1)*;Cunningham, G.(1);Lim, S.(1);Dawson, P.(1);Kottoor, S.H.(2);Bheekhun, Z.(1);Anderson, S.(1);Mawdsley, J.(1);Ray, S.(1);Powell, N.(2);Dart, R.(1);Rawstron, K.(3);Arkir, Z.(4);Irving, P.M.(1);
(1)Guy@E@s & St Thomas@E@ Hospital, Gastroenterology, London, United Kingdom;(2)Imperial College London, Gastroenterology, London, United Kingdom;(3)Synnovis, St Thomas@E@ Hospital, London, United Kingdom;(4)Barts Health NHS Trust, London Pathology Partnership, London, United Kingdom;FAVOUR (Investigation of the Faecal loss of Vedolizumab and its role in influencing serum drug levels Outcomes and Response in ulcerative colitis)
P1015: Subcutaneous infliximab effectively manages clinical outcomes of Inflammatory Bowel Disease independently of various confounding factorsECCO'24Year: 2024
Authors: Buisson, A.(1)*;Cummings, F.(2);Subramanian, S.(3);Rahmany, S.(4);Fumery, M.(5);Kwon, B.(6);Park, S.(6);Lee, Y.N.(6);Smith, P.J.(7);
(1)Clermont Auvergne University, IBD Unit, Clermont-Ferrand, France;(2)Southampton General Hospital, Gastroenterology, Southampton, United Kingdom;(3)Cambridge University Hospital NHS Trust, Gastroenterology, Cambridge, United Kingdom;(4)University Hospital Southampton NHS Foundation Trust, Gastroenterology, Southampton, United Kingdom;(5)CHU Amiens Picardie, Hepatogastroenterology, Amiens, France;(6)Celltrion Healthcare, Medical Department, Incheon, Korea- Republic Of;(7)Royal Liverpool Hospital, Gastroenterology, Liverpool, United Kingdom;
P1016: Real-world data on sequential therapy in moderate-to-severe UC: Unveiling second-line strategies after anti-TNF failureECCO'24Year: 2024
Authors: Farkas, B.(1)*;Borsos, M.(2);Resál, T.(3);Bacsur, P.(1);Szepes, Z.(1);Savarino, E.V.(4,5);Bertin, L.(4,5);Limdi, J.K.(6);Sethi-Arora, K.(6);Miheller, P.(7);Vilmos , F.(7);Castiglione, F.(8);Bonacci, L.(8);Lukas, M.(9);Maharshak, N.(10,11);Berman, G.(10,11);Krznarić, Ž.(12);Wetwittayakhlang, P.(13,14);Lakatos, P.L.(13,15);Seidelin, J.B.(16);Attauabi, M.(16);Michalopoulos, G.(17);Ribaldone, D.G.(18);Kagramanova, A.(19);Chashkova, E.(20);Sarlós, P.(21,22);Saibeni, S.(23);Shitrit, A.B.G.(24);Molnár, T.(1);Farkas, K.(1);
(1)University of Szeged, Department of Internal Medicine, Szeged, Hungary;(2)AdWare Research, Department of Biostatistics, Balatonfüred, Hungary;(3)University of Szeged, Department of Biostatistics, Szeged, Hungary;(4)Azienda Ospedale Università of Padua, Gastroenterology Unit, Padua, Italy;(5)University of Padua, Department of Surgery- Oncology and Gastroenterology, Padua, Italy;(6)Northern Care Alliance NHS Foundation Trust, Division of Gastroenterology, Manchester, United Kingdom;(7)Semmelweis University, Department of Surgery- Transplantation and Gastroenterology, Budapest, Hungary;(8)University of Naples Federico II, Gastroenterology Department of Clinical Medicine and Surgery, Naples, Italy;(9)ISCARE IVF Clinical Center Českomoravská, Clinical and Research Centre for Inflammatory Bowel Diseases, Prague, Czech Republic;(10)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(11)Tel Aviv Sourasky Medical Center, Department of Gastroenterology and Hepatology, Tel Aviv, Israel;(12)University Hospital Zagreb, Department of Internal Medicine- Clinical Unit of Clinical Nutrition, Zagreb, Croatia;(13)McGill University Health Centre, Division of Gastroenterology, Montreal, Canada;(14)Prince of Songkla University- Hat Yai, Gastroenterology and Hepatology Unit- Faculty of Medicine, Songkhla, Thailand;(15)Semmelweis University, Department of Internal Medicine and Oncology, Budapest, Hungary;(16)Copenhagen University Hospital - Herlev and Gentofte, Department of Gastroenterology and Hepatology, Herlev, Denmark;(17)General Hospital of Athens @D@G. Gennimatas@D@, Gastroenterology Department, Athens, Greece;(18)University of Turin, Department of Medical Sciences, Turin, Italy;(19)Moscow Clinical Scientific Center named after A. S. Loginov, Clinical Research, Moscow, Russian Federation;(20)Irkutsk Regional Hospital, Department of Coloproctology, Irkutsk, Russian Federation;(21)University of Pécs, Division of Gastroenterology- First Department of Medicine, Pécs, Hungary;(22)University of Pécs, Institute for Translational Medicine, Pécs, Hungary;(23)Rho Hospital- ASST Rhodense, Gastroenterology Unit, Milan, Italy;(24)Shaare Zedek Medical Center- Affiliated with the Medical School- Hebrew University, IBD MOM Unit- Digestive Diseases Institute, Jerusalem, Israel;
P1017: Upadacitinib as rescue therapy for the treatment of Acute Severe Colitis in an acute care settingECCO'24Year: 2024
Authors: Clinton, J.(1);Motwani, K.(1);Schwartz, S.(2);McCarthy, P.(3);Axelrad, J.(4);Cross, R.(1)*;George, L.(1);
(1)University of Maryland School of Medicine, Internal Medicine- Gastroenterology and Hepatology, Baltimore, United States;(2)Mercy Medical Center, Internal Medicine- Gastroenterology and Hepatology, Baltimore, United States;(3)University of Maryland School of Medicine, Internal Medicine, Baltimore, United States;(4)NYU Grossman School of Medicine, Internal Medicine- Gastroenterology, New York, United States;
P1018: Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with moderately to severely active Ulcerative ColitisECCO'24Year: 2024
Authors: Thakre, N.(1)*;Goebel, A.(1);D@E@Cunha, R.(2);Winzenborg, I.(1);Liu, W.(2);Pang, Y.(2);
(1)AbbVie, Clinical Pharmacology, Ludwigshafen, Germany;(2)AbbVie, Clinical Pharmacology, North Chicago, United States;
P1019: @D@Totality-of-the-evidence@D@ of proposed ustekinumab biosimilar SB17@D@ECCO'24Year: 2024
Authors: Armuzzi, A.(1)*;Girolomoni, G.(2);Feldman, S.(3);Goncalves, J.(4);Park, Y.(5);Ye, B.D.(6);
(1)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;(2)University of Verona, Dermatology, Verona, Italy;(3)Wake Forest University School of Medicine, Dermatology, Winston Salem, United States;(4)Universidade de Lisboa, Faculty of Pharmacy, Lisbon, Portugal;(5)Samsung Bioepis Co.- Ltd, Medical Affairs, Incheon, Korea- Republic Of;(6)Asan Medical Center- University of Ulsan College of Medicin, Gastroenterology- Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;
P101: Investigating the role of gut eukaryotic virome in contributing to colorectal cancer carcinogenesisECCO'24Year: 2024
Authors: Facoetti, A.(1)*;Massimino, L.(1,2);Cagliani, S.(1);Spanò, S.(1,2);Nicolò, S.(1);Errico, C.(1);Parigi, T.L.(1,2);Danese, S.(2,3);Ungaro, F.(1,2);
(1)San Raffaele Scientific Institute, Division of Immunology- Transplantation- and Infectious Diseases - Experimental Gastroenterology Laboratory, Milan, Italy;(2)San Raffaele Hospital, Gastro Center- Gastroenterology and Digestive Endoscopy, Milan, Italy;(3)San Raffale Scientific Institute, Division of Immunology- Transplantation- and Infectious Diseases, Milan, Italy;Experimental Gastroenterology Laboratory
